Abstract
Synthesis de novo, acquisition by salvage and interconversion of purines and pyrimidines represent the fundamental requirements for their eventual assembly into nucleic acids as nucleotides and the deployment of their derivatives in other biochemical pathways. A small number of drugs targeted to nucleotide metabolism, by virtue of their effect on folate biosynthesis and recycling, have been successfully used against apicomplexan parasites such as Plasmodium and Toxoplasma for many years, although resistance is now a major problem in the prevention and treatment of malaria. Many targets not involving folate metabolism have also been explored at the experimental level. However, the unravelling of the genome sequences of these eukaryotic unicellular organisms, together with increasingly sophisticated molecular analyses, opens up possibilities of introducing new drugs that could interfere with these processes. This review examines the status of established drugs of this type and the potential for further exploiting the vulnerability of apicomplexan human pathogens to inhibition of this key area of metabolism
Keywords: Plasmodium, Toxoplasma, Cryptosporidium, nucleotide biosynthesis, salvage pathways, drug resistance, drug targets, folate metabolism
Current Drug Targets
Title: Targeting Purine and Pyrimidine Metabolism in Human Apicomplexan Parasites
Volume: 8 Issue: 1
Author(s): John E. Hyde
Affiliation:
Keywords: Plasmodium, Toxoplasma, Cryptosporidium, nucleotide biosynthesis, salvage pathways, drug resistance, drug targets, folate metabolism
Abstract: Synthesis de novo, acquisition by salvage and interconversion of purines and pyrimidines represent the fundamental requirements for their eventual assembly into nucleic acids as nucleotides and the deployment of their derivatives in other biochemical pathways. A small number of drugs targeted to nucleotide metabolism, by virtue of their effect on folate biosynthesis and recycling, have been successfully used against apicomplexan parasites such as Plasmodium and Toxoplasma for many years, although resistance is now a major problem in the prevention and treatment of malaria. Many targets not involving folate metabolism have also been explored at the experimental level. However, the unravelling of the genome sequences of these eukaryotic unicellular organisms, together with increasingly sophisticated molecular analyses, opens up possibilities of introducing new drugs that could interfere with these processes. This review examines the status of established drugs of this type and the potential for further exploiting the vulnerability of apicomplexan human pathogens to inhibition of this key area of metabolism
Export Options
About this article
Cite this article as:
Hyde E. John, Targeting Purine and Pyrimidine Metabolism in Human Apicomplexan Parasites, Current Drug Targets 2007; 8 (1) . https://dx.doi.org/10.2174/138945007779315524
DOI https://dx.doi.org/10.2174/138945007779315524 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential Health Benefits of Algae and Micro Algae in Medicine: A Review on Spirulina platensis
Current Nutrition & Food Science Drug Targets in Infections with Ebola and Marburg Viruses
Infectious Disorders - Drug Targets Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews Nicotine and Nicotinic Receptor Involvement in Neuropsychiatric Disorders
Current Topics in Medicinal Chemistry Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade
Current Neuropharmacology Minocycline Mediated Mitochondrial Cytoprotection: Premises for Therapy of Cerebrovascular and Neurodegenerative Diseases
Current Drug Targets Applied Proteomics in Companion Animal Medicine
Current Proteomics Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Editorial [Hot Topic: Protein Peptide Informatics and Drug Designing (Guest Editor: Rajani R. Joshi)]
Protein & Peptide Letters Opiate Addiction Therapies and HIV-1 Tat: Interactive Effects on Glial [Ca<sup>2+</sup>]<sub>i</sub>, Oxyradical and Neuroinflammatory Chemokine Production and Correlative Neurotoxicity
Current HIV Research Advances in Oncolytic Virus Therapy for Glioma
Recent Patents on CNS Drug Discovery (Discontinued) Bioinformatics Comparison of G Protein of Isfahan Virus with the Same Proteins of Two Other Closely Related Viruses of the Genus Vesiculovirus
Protein & Peptide Letters Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Editorial (Thematic Issue: MiRNAcles in the Brain: What to Wish and What to Fear)
CNS & Neurological Disorders - Drug Targets Blood Pressure Measurement: Lessons Learned from Our Ancestors
Current Pharmaceutical Design Antiviral Treatment of Chikungunya Virus Infection
Infectious Disorders - Drug Targets Regulation of Ocular Immune Responses by Corneal Epithelium
Current Immunology Reviews (Discontinued) True or False? Activations of Language-related Areas in Patients with Disorders of Consciousness
Current Pharmaceutical Design